Trial Profile
To evaluate safety, pharmacokinetics and pharmacodynamics of obeticholic acid in patients with compensated cirrhosis due to Nonalcohlic steatohepatitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2018
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 10 Dec 2018 New trial record
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases